2 studies on Somatostatin mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**Clinicians and biohackers using sermorelin or GHRP-2** should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. **Reducing AVF before or a…
**Clinicians and peptide users designing GH-stimulation protocols in women must account for menopausal status and concurrent estrogen exposure, not just dosing of the secretagogue itself.** The finding that GHRP-2 out…